SCHEMBL7572500

SCHEMBL7572500

N#Cc1ccc(S(=O)(=O)Nc2ccc(Cl)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.73
KDM1A O60341 1/20 0.64
CYP19A1 P11511 2/20 0.62
MAPT P10636 2/20 0.59
NPSR1 Q6W5P4 1/20 0.59
ALDH1A1 P00352 2/20 0.58
PRMT1 Q99873 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
AR P10275 1/20 0.57
PGR P06401 1/20 0.55
BRD4 O60885 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
HTT P42858 2/20 0.54
LMNA P02545 1/20 0.54
TSHR P16473 1/20 0.54
NLRP3 Q96P20 1/20 0.54
TP53 P04637 1/20 0.53
THRB P10828 1/20 0.53
AVPR2 P30518 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6554559 1.00 CES1 (0.73) CES1KDM1ACYP19A1MAPTNPSR1
SCHEMBL29561475 0.89 KDM1A (0.59) CES1KDM1ACYP19A1ARPGR
SCHEMBL6554630 0.86 CES1 (1.00) CES1CYP19A1MAPTALDH1A1PRMT1
SCHEMBL2474197 0.86 CES1 (1.00) CES1CYP19A1MAPTALDH1A1PRMT1
SCHEMBL7475857 0.85 CES1 (0.76) CES1CYP19A1MAPTNPSR1ALDH1A1
SCHEMBL96241 0.83 KDM1A (0.64) CES1KDM1ACYP19A1MAPTALDH1A1
SCHEMBL6555449 0.83 KDM1A (0.68) KDM1ACYP19A1MAPTALDH1A1TDP1
SCHEMBL7281538 0.83 KDM1A (0.68) KDM1ACYP19A1MAPTARBRD4
SCHEMBL27888183 0.83 CA1 (0.65) KDM1ACYP19A1MAPTALDH1A1PRMT1
SCHEMBL14645822 0.83 CYP19A1 (0.75) KDM1ACYP19A1ALDH1A1ARCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2017-06-15 US disclosed
WO-2016016421-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2016-02-04 WO disclosed
EP-1239852-A2 BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS Arrow Therapeutics Limited (GB) 2002-09-18 EP disclosed
WO-2001028537-A2 BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS ARROW THERAPEUTICS LIMITED (GB) 2001-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS ALOX5, ALOX15, ALOX12 CES1 172/4885KDM1A 3043/4885CYP19A1 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.